Pharmaceutical Technology

APRIL 10, 2023

Health director-general Tan Sri Dr Noor Hisham Abdullah stated that the approval of Evusheld was granted at the 383rd Drug Control Authority (DCA) meeting. Evusheld (formerly AZD7442) is a combination of two long-acting antibodies, tixagevimab (AZD8895) and cilgavimab (AZD1061).

Immune Response 264

Immune Response Antibody Vaccination Vaccine 264

Drug Discovery World

JANUARY 3, 2023

A monoclonal antibody to prevent Covid-19 in vulnerable patients, AZD3152, has entered clinical trials less than 12 months after discovery. . Hugo Fry, CEO of RQ Bio, comments: “We’re delighted that one of our discovered antibodies is now at the core of an innovative AstraZeneca investigational medicine reaching clinical trials.” .

Antibody 52

Antibody Development Immune Response Clinical Trials 52

Drug Discovery World

MAY 2, 2024

A study led by the University of Oxford has successfully investigated human immunity against Covid-19 in people who already have antibodies, with the aim of advancing future vaccines and treatments. The data from this COVCHIM01 study showed durable immunity post-infection/vaccination against the original Covid-19 virus.

Vaccination 59

Vaccination Vaccine Development Immune Response 59

Drug Discovery World

AUGUST 16, 2023

Researchers have shown that a novel antibody has greater activity and potentially fewer side effects than existing biological therapies for conditions such as rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD).

Antibody 52

Antibody Immune Response Protein Research 52

NY Times

MAY 11, 2022

Antibody levels rose in the children who received it, suggesting the vaccine protects against infection. But the data were gathered before the arrival of Omicron.

Immune Response 62

Immune Response Vaccination Vaccine Antibody 62

Pharmaceutical Technology

MAY 12, 2023

The collaboration will use the integrated drug creation platform of Absci and the clinical immunology datasets from the Kennedy Institute to identify antibodies to immune-mediated inflammatory diseases and autoimmune conditions with unprecedented speed.

Development 130

Development Antibody Immune Response Genome 130

Pharmaceutical Technology

JUNE 28, 2022

Astellas Pharma and Sutro Biopharma have entered a global, strategic partnership and licencing agreement to discover and develop new immunostimulatory antibody-drug conjugates (iADCs). An iADC merges an antibody with a small molecule compound that elicits immunogenic cell death, and an immune-activating molecule.

Development 264

Development Antibody Immune Response Production 264

Drug Discovery World

JANUARY 11, 2023

AbbVie and Immunome have agreed a worldwide collaboration with the aim of discovering up to 10 novel antibody-target pairs arising from three specified tumour types using Immunome’s Discovery Engine. . The post Collaboration to identify up to 10 novel target-antibody pairs appeared first on Drug Discovery World (DDW).

Antibody 52

Antibody Engineer Immune Response Sales 52

Pharmaceutical Technology

MAY 19, 2023

OncoResponse has secured a $13m grant from the Cancer Prevention and Research Institute of Texas (CPRIT) and raised an additional $14m in funding from investors for advancing OR502 to investigational new drug (IND) and clinical trials. It is planned to enter clinical studies this year. ”

Immune Response 130

Immune Response Clinical Trials Clinical Trials Antibody 130

Drug Discovery World

AUGUST 25, 2023

For comparison, Schulz said, three new anti-amyloid antibodies used to treat AD have shown they slow disease progression by 25%, 27%, and 35%. Enhancing the efficiency of immune cells “We hypothesise that the reduced risk of AD associated with vaccines is likely due to a combination of mechanisms,” another researcher Avram Bukhbinder said.

Antibody 52

Antibody Vaccination Vaccine Protein 52

XTalks

JUNE 18, 2021

This is why Regeneron’s announcement of positive clinical trial results that show its antibody cocktail treatment can cut deaths among hospitalized patients is welcome news. It is the first trial to demonstrate that any antibody treatment could improve survival in patients hospitalized with COVID-19. Regeneron Pharmaceuticals Inc.’s

Antibody 75

Antibody Immune Response Trials Clinical Trials 75

STAT News

DECEMBER 23, 2022

Food and Drug Administration approved a new treatment for patients with follicular lymphoma, a slow-growing type of blood cancer, said Genentech , its maker and a subsidiary of Roche. In a clinical trial, 60% of patients with follicular lymphoma treated with Lunsumio achieved a complete response. Happy holidays from all of us.

FDA Approval 98

FDA Approval Immune Response Drugs Research 98

Drug Discovery World

FEBRUARY 28, 2024

Lu Rahman selects some of the year’s interesting and noteworthy advances in cancer research drug discovery and development. As always, a year within cancer drug discovery and development brings with it significant breakthroughs, and 2023 has been no exception. Research into new cancer drugs remain strong. expressing cancers.

Development 64

Development Research Drugs Antibody 64

Pharmaceutical Technology

DECEMBER 16, 2022

The example of rituximab, originally a cancer drug, now used for lupus, has shown the potential of adopting cancer medications for lupus. Furthermore, drug-free remission was maintained during longer follow-up and even beyond the reappearance of B cells.

Immune Response 147

Immune Response Marketing Antibody Trials 147

Pharmaceutical Technology

APRIL 28, 2023

Therini Bio will use part of the funds to advance its potential first-in-class investigational antibody, THN391, into clinical trials. THN391 binds the inflammation-driving component of fibrin, known for activating the immune responses in neurodegenerative and ophthalmologic diseases.

Development 130

Development Immune Response Clinical Trials Clinical Trials 130

Pharmaceutical Technology

JUNE 5, 2023

According to GlobalData, Phase I drugs for Pediatric Diffuse Intrinsic Pontine Glioma does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Kid EDV LoA Report. Buy the report here.

Immune Response 130

Immune Response Clinical Trials Clinical Trials Development 130

The Pharma Data

SEPTEMBER 14, 2020

Illustration of antibodies attacking the coronavirus. A new antibody treatment is to be trialled on Covid-19 patients in UK hospitals. Monoclonal antibodies, which are potent, laboratory-made antibodies, will be given to about 2,000 people to see if they are effective against coronavirus. What are monoclonal antibodies?

Antibody 52

Antibody Trials Immune Response Vaccination 52

pharmaphorum

JUNE 16, 2021

People who cannot generate an effective immune response against COVID-19 can be protected with an infusion of Regeneron’s antibody therapy REGN-COV, according to new data from the UK RECOVERY trial. 37% of the standard care group deteriorated to that point, compared to 30% of those on Regeneron’s drug.

Antibody 98

Antibody Drugs Immune Response Trials 98

Pharmaceutical Technology

MAY 17, 2023

The treatment is an investigational first-in-class monoclonal anti-human complement factor C5a antibody. It has been designed for controlling the complement factor C5a, which is a protein that plays an important and harmful role in the immune response of the body.

Manufacturing 130

Manufacturing Immune Response Protein Antibody 130

XTalks

AUGUST 14, 2023

The Janssen Pharmaceutical Companies of Johnson & Johnson announced that its bispecific antibody Talvey (talquetamab-tgvs) received US Food and Drug Administration (FDA) approval as a fifth-line treatment for adult patients with heavily pretreated multiple myeloma. Results were similar at the higher 0.8

FDA Approval 97

FDA Approval Antibody Immune Response Drugs 97

Drug Discovery World

MARCH 26, 2024

The US Food and Drug Administration (FDA) has granted emergency use authorisation (EUA) to half-life extended monoclonal antibody (mAb) Pemgarda (pemivibart, or VYD222) for the pre-exposure prophylaxis (prevention) of Covid-19.

FDA Approval 52

FDA Approval Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

FEBRUARY 19, 2024

At all assessed doses, RBI-4000 was well-tolerated and achieved a strong immune response, with protective virus-neutralising antibody titers above the World Health Organization (WHO)-defined immune surrogate level of protection against the rabies virus.

Vaccination 52

Vaccination Vaccine Immune Response RNA 52

Drug Discovery World

APRIL 11, 2024

We have noted that cancer patients can develop powerful anti-tumour immune responses that can result in complete cure of the disease and we call these patients ‘elite responders’. By understanding what triggers the adaptive immune response in “elite responders” we have identified new targets and therapeutic antibodies.

Research 59

Research Immune Response Antibody Medicine 59

Drug Discovery World

JANUARY 12, 2024

This week has seen a number of significant discoveries by researchers in academic institutions, in some cases in partnership with industry, emphasising the important role universities play in early-stage drug discovery. The post This week in drug discovery (8-12 January) appeared first on Drug Discovery World (DDW).

Drugs 52

Drugs Immune Response Allergies Bacteria 52

The Pharma Data

NOVEMBER 22, 2020

FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and fully human antibodies, today announced they have signed an agreement to discover antibodies with Pandion Therapeutics (Pandion). PORTO, Portugal & CAMBRIDGE, England & LONDON–( BUSINESS WIRE )– FairJourney Biologics S.A (FJB)

Antibody 52

Antibody Immune Response Engineer Protein 52

XTalks

MAY 2, 2024

In 2023, the US Food and Drug Administration (FDA) approved a record-breaking 61 drugs, the most in history. Since January, the FDA has already signed off on more than a dozen novel drugs. The agency is reviewing applications for several highly anticipated drugs for approval in 2024.

Drugs 52

Drugs FDA Approval Sales Vaccination 52

Pharmaceutical Technology

AUGUST 18, 2022

According to the findings, a third dose induced greater immune responses similar to or surpassing levels linked to protection in Phase III trials. Nuvaxovid vaccine elicited a substantial antibody response when administered as a heterologous third booster dose in the COV-BOOST trial.

Immune Response 130

Immune Response Vaccination Vaccine Protein 130

pharmaphorum

JUNE 28, 2022

billion partnership with US biotech Sutro Biopharma for a series of antibody-drug conjugates for cancer, focusing on applications in patients who don’t respond to current immunotherapies. Astellas has agreed a $1.36 The alliance includes an upfront payment of $90 million, backed by $422.5

Antibody 101

Antibody Immune Response Gene Therapy Drugs 101

XTalks

AUGUST 8, 2022

MiroBio is a private biotech company based in the UK that focuses on developing checkpoint agonist antibodies, which are a new class of therapies that work to restore immune balance in patients with autoimmune and inflammatory diseases. PD-1 is a potent immune inhibitory receptor. MiroBio’s Research Pursuits.

Immune Response 98

Immune Response Antibody Life Science Engineer 98

pharmaphorum

DECEMBER 12, 2022

Johnson & Johnson is in pole position to bring a drug targeting GPRC5D to market as a new therapeutic approach to multiple myeloma, and told delegates at ASH yesterday why its talquetamab candidate should be viewed as an important new option for the blood cancer. mg/kg dose and 73% at a 0.8 mg/kg dose and 73% at a 0.8

Antibody 52

Antibody Drugs Immune Response Trials 52

pharmaphorum

OCTOBER 11, 2022

An intranasal formulation of AstraZeneca’s widely-used COVID-19 vaccine Vaxzevria has failed at the first hurdle, after results from a phase 1 trial found it was unable to stimulate a strong immune response to the virus. “The authors acknowledge certain limitations of the study, including small numbers of participants.

Vaccination 113

Vaccination Vaccine Immune Response Development 113

XTalks

NOVEMBER 22, 2022

Provention Bio’s Tzield (teplizumab) has won US Food and Drug Administration (FDA) approval to delay the onset of stage 3 type 1 diabetes in adults and pediatric patients eight years of age and older who have stage 2 type 1 diabetes. Provention Bio came to a commercialization agreement with Sanofi last month to market the drug in the US.

Insulin 97

Insulin Drugs FDA Approval Immune Response 97

pharmaphorum

SEPTEMBER 15, 2020

Humanigen is hoping for emergency use authorisation in the US for an antibody to treat severe COVID-19 before the end of 2020, and has teamed up with Swiss contract manufacturer Lonza to make sure it can meet demand. They looked at safety as well as carrying out a futility analysis to gauge whether the drug was working as expected.

Drugs 92

Drugs Antibody Contract Manufacturing Manufacturing 92

The Pharma Data

SEPTEMBER 17, 2020

The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus. The test targets antibodies against the spike protein. Food and Drug Administration (FDA). This is the focus of vaccines in development and convalescent plasma therapy.

Antibody 52

Antibody Vaccination Vaccine In-Vitro 52

pharmaphorum

JUNE 30, 2021

Just a few months after starting clinical trials of its nasal spray vaccine for COVID-19, US biotech Altimmune is abandoning the project, saying that it generated weaker than expected immune responses in a phase 1 trial. . We believe that prior immunity in humans may be important for a robust immune response to intranasal dosing.”

Vaccination 98

Vaccination Vaccine Trials Immune Response 98

pharmaphorum

DECEMBER 17, 2020

UK-based EUSA Pharma has begun a late-stage trial of its antibody siltuximab in COVID-19, hoping that the IL-6 inhibitor will succeed where class rivals from Roche and Sanofi/Regeneron have failed. EUSA Pharma bought global rights to the drug from Janssen in $115 million. Feature image courtesy of Rocky Mountain Laboratories/NIH.

Drugs 103

Drugs Immune Response Trials Clinical Trials 103

pharmaphorum

JULY 6, 2021

It also said that the tumour response was aligned to the level of HER2-targeting antibodies generated by the vaccine, which is given as three doses over a 35-day period. ” The anti-HER2 market is advancing rapidly however, with a new generation of drugs coming through the industry pipeline.

Vaccination 117

Vaccination Vaccine Trials Antibody 117